Summary: Researchers have identified a significant safety concern linking commonly prescribed glucagon-like peptide-1 (GLP-1) receptor agonists—such as semaglutide, tirzepatide and liraglutide—to an increased incidence of clinically meaningful hypotensive episodes, including severe dizziness, fainting and fall-related injuries.
Using electronic health records from more than 42,000 adults who were already taking at least two classes of antihypertensive medications, investigators observed a rapid and statistically significant rise in low blood pressure events within six months of initiating GLP-1 therapy. The pattern persisted at 12 months and was most pronounced in older adults and people with Type 2 diabetes.
The analysis suggests the risk is not explained by weight loss alone but likely involves direct cardiovascular and autonomic mechanisms. These findings underline the importance of careful clinical monitoring and planned medication de‑escalation when starting GLP-1 drugs in patients treated for hypertension.
Key Facts
- Hypotensive escalation: Within six months of beginning GLP-1 therapy, documented low blood pressure events rose from 8.7% to 10.2% among patients on multi-drug hypertension regimens. The elevated risk remained statistically significant at 12 months.
- How events were defined: The study tracked objective, real-world markers of clinical hypotension: formal low blood pressure diagnoses, systolic readings below 90 mm Hg, new prescriptions for hypotension treatments, and sudden episodes of dizziness, fainting or falls.
- Older adults at highest risk: Adults aged 65 and older represented 37% of the cohort but accounted for 53% of all hypotensive events, reflecting age-related vascular vulnerability.
- People with Type 2 diabetes: Patients with diabetes were overrepresented among those who fainted or had low blood pressure spikes—75% of events occurred in people with Type 2 diabetes, although they comprised 63% of the study population—consistent with diabetes-related autonomic dysfunction.
- Not just weight loss: Secondary analyses indicated that weight reduction alone did not account for the increased risk, pointing to additional, direct physiological effects of GLP-1 receptor agonists on cardiovascular and autonomic control.
- Preventable with medication review: The study authors emphasize that many hypotensive events are identifiable and avoidable. Because GLP-1 medications can markedly improve metabolic and vascular status, clinicians should proactively reassess and often reduce or discontinue existing blood pressure medications to prevent over‑treatment.
- Telehealth caution: The researchers warn about automated, remote prescribing of GLP-1s without direct clinical follow-up. Such pathways may fail to monitor blood pressure or evaluate symptoms of standing-induced lightheadedness, increasing the risk of head injury, fractures or motor vehicle crashes.
Source: Northwestern University
Northwestern Medicine scientists used health record data to examine the safety profile of GLP-1 receptor agonists in people with metabolic cardiovascular and renal disease. Their retrospective analysis followed more than 42,000 adults who were taking at least two different antihypertensive drug classes and who started semaglutide, tirzepatide or liraglutide.
The peer-reviewed findings are scheduled for presentation at ENDO 2026, the Endocrine Society’s annual meeting.
The authors emphasize that GLP-1 drugs remain highly beneficial for many patients and reduce cardiovascular risk in many settings. Still, they recommend heightened vigilance in specific populations because hypotension can lead to serious injury or death if not anticipated and managed.
The research team tracked hypotensive events at six, 12 and 24 months after GLP-1 initiation and compared event rates with the pre‑GLP-1 period. Events included recorded dizziness, syncope, falls, low blood pressure diagnoses, systolic blood pressure values below 90 mm Hg and new prescriptions for hypotension medications.
A patient treated for hypertension who experienced dizziness after starting a GLP‑1 medication is available for interview to describe the real-world impact of these symptoms.
Key findings
- At six months after starting GLP‑1 therapy, hypotensive events increased from 8.7% to 10.2%.
- The increased event rate persisted at 12 months (from 13.6% to 14.3%).
- Older adults (65+) accounted for a disproportionate share of events (53% of events vs. 37% of the cohort).
- People with Type 2 diabetes represented 75% of hypotensive events while comprising 63% of the total study population.
- Secondary analyses showed weight loss did not fully explain the rise in hypotension, pointing to additional drug-related mechanisms.
Below is a condensed Q&A with study senior author Dr. Micah Eimer, summarizing clinical implications and next steps.
Q: Why investigate GLP‑1s and hypotension?
“GLP‑1s are widely prescribed because they substantially improve metabolic health and can lower cardiovascular risk. Clinically, we observed patients reporting lightheadedness and fainting after starting GLP‑1s, with exam-confirmed low blood pressure. Given the potential severity of hypotension, we designed this study to quantify the risk and identify who is most vulnerable.”
Q: How clinically important is a 1.5% increase in hypotensive events?
“The increase is statistically significant and clinically meaningful: hypotension can cause falls, head injuries, fractures and fatal accidents. Importantly, many cases are preventable through proactive medication review and monitoring.”
Q: What should patients do?
“Patients starting GLP‑1 therapy should work with their prescribing clinician to monitor blood pressure and symptoms. If dizziness or near‑syncope occurs, it may indicate an interaction with existing blood pressure medications that warrants prompt adjustment.”
Q: Why are older adults and people with diabetes most affected?
“Older adults often have stiffer arteries and vascular disease that make them more symptomatic when blood pressure drops. People with diabetes may have autonomic dysfunction that impairs blood pressure regulation. There may also be direct GLP‑1 effects on cardiovascular and autonomic systems that require further study.”
The study is titled, “GLP1 Receptor Agonists and the Risk of Significant Hypotension Among Patients with Metabolic Cardiovascular Renal Disease: Too Much of A Good Thing?” and the authors call for additional research to confirm these findings and refine monitoring recommendations.
Key Questions Answered:
A: When GLP‑1 medications are added to an existing regimen of blood pressure drugs, their independent cardiovascular effects and metabolic improvements can interact with older prescriptions and lower blood pressure further than intended, producing symptomatic hypotension on standing or with activity.
A: Adults 65 and older and people with Type 2 diabetes are at highest risk: age-related vascular changes and diabetes-related autonomic dysfunction reduce the body’s ability to compensate for sudden blood pressure drops.
A: Prevention requires direct clinical supervision and a proactive medication de‑escalation plan. Starting a GLP‑1 should trigger a review of current blood pressure medications, with reductions or discontinuations as clinically appropriate. Avoid unmanaged online prescribing without blood pressure monitoring.
Editorial Notes:
- This article was edited by a Neuroscience News editor.
- The journal paper was reviewed in full by the editorial team.
- Additional context was added by staff to clarify clinical implications.
About this neurodevelopment and aging research news
Author: Ben Schamisso
Source: Northwestern University
Contact: Ben Schamisso – Northwestern University
Image: The image is credited to Neuroscience News
Original Research: Findings to be presented at ENDO 2026